Akums Launches Lasmiditan Dispersible Tablets for Migraine Relief

Akums Drugs & Pharmaceuticals has launched Lasmiditan dispersible tablet aimed at providing faster and easier relief during acute migraine attacks.

Approved by the Drugs Controller General of India (DCGI), this new formulation addresses a common challenge for migraine patients: taking medication when nausea or difficulty swallowing makes regular pills hard to manage.

The Lasmiditan dispersible tablet for acute migraine offers a patient-friendly solution. Users can dissolve the tablet in a small amount of water, ensuring quicker intake and faster action when symptoms of migraine strike. This approach is particularly beneficial for adults experiencing sudden pain, light or sound sensitivity, and nausea during migraine episodes.

Also Read: Advanced Formulation Technologies Streamlining Global Pharma Innovation

Akums designed the tablet with a dual disintegration system that combines swelling and effervescence for rapid dispersion. Advanced taste-masking technology further improves patient experience by reducing the drug’s natural bitterness. This ensures that patients can take the medicine comfortably and promptly during an acute migraine attack.

Lasmiditan belongs to the newer class of ditans, which work by activating serotonin 5?HT1F receptors on sensory neurons involved in migraine pain pathways. Unlike older treatments, it relieves pain without constricting blood vessels, making it suitable for adults with migraine with or without aura. However, it is intended for acute migraine relief and is not a preventive therapy.

In a statement, Akums emphasized that this launch reflects its commitment to patient-centric innovation in pharmaceuticals. By combining fast-acting therapy with an easy-to-take dispersible form, Akums aims to make acute migraine treatment more effective and accessible across India.